Duke Cancer Institute

Leading Clinical Research Innovator, Amy Abernethy, M.D., Ph.D., Joins insitro Board of Directors

Retrieved on: 
Wednesday, April 3, 2024
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Data Management, Science, Artificial Intelligence, Principal, Hospice, Drug discovery, Intelligence, Patient, Software, Health policy, Duke Cancer Institute, Drug development, Machine learning, FDA, Medical device

insitro, a machine learning-powered drug discovery and development company, today announced that Amy Abernethy, M.D., Ph.D, has joined the company’s board of directors.

Key Points: 
  • insitro, a machine learning-powered drug discovery and development company, today announced that Amy Abernethy, M.D., Ph.D, has joined the company’s board of directors.
  • In that role, Dr. Abernethy oversaw the FDA’s vision and execution on the use of data and technology in clinical development.
  • There, she led teams in the development and delivery of software and data products that bridge the gap between clinical research and care.
  • “Amy has a career-long track record of leading high-impact initiatives that leverage clinical data to enable research and development, and accelerate the path of bringing medicines to patients,” said Daphne Koller, Ph.D., CEO and founder of insitro.

Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®

Retrieved on: 
Friday, February 23, 2024
Tandem, Therapy, Infection, MD, TCT, FDA, Bone marrow, Cell, Health, Hematology, Society, Duke Cancer Institute, Science, White, Non-Hodgkin lymphoma, Patient, Fungal infection, NK, NAM, Rated R, Transplant, Rituximab, Cytokine release syndrome, EAP, Lymphoma, Pharmaceutical industry

BOSTON, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today presented data highlighting its expanded access program (EAP) for FDA-approved allogeneic stem cell therapy Omisirge® (omidubicel-onlv) and Phase 1 data for its allogeneic cryopreserved natural killer (NK) cell therapy candidate GDA-201 at the 2024 Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). The hybrid meetings take place February 21-24 virtually and in person in San Antonio, Texas.

Key Points: 
  • The hybrid meetings take place February 21-24 virtually and in person in San Antonio, Texas.
  • “The data presented at Tandem provide further evidence of the potential of Gamida Cell’s nicotinamide (NAM) technology to develop potentially curative therapies by expanding and enhancing cells,” said Ronit Simantov, MD, Chief Medical and Scientific Officer of Gamida Cell.
  • It allowed for institutional variability in conditioning regimens and supportive care, more closely reflecting the real-world environment.
  • Patients were heavily pretreated with a median of six prior lines of therapy including CAR-T cell therapy and hematopoietic stem cell transplant.

Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients

Retrieved on: 
Thursday, February 8, 2024
GBM, Type 1, Duke Cancer Institute, Survival, Safety, Convection, Patient, Decompression (diving), Journal, Pharmaceutical industry

CARDIFF, United Kingdom, February 8, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare/orphan brain cancers, today provided survival updates from its MAGIC-G1 study (NCT05324501) of MTX110 in patients with recurrent glioblastoma (“rGBM”) being conducted at Duke Cancer Institute and Baptist MD Anderson Cancer Center.

Key Points: 
  • In October 2023, Biodexa announced completion of recruitment of Cohort A of an ongoing open-label Phase I dose-escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery (“CED”) via implanted refillable pump and catheter.
  • Because no drug-related adverse events were observed within the first 30 days from start of treatment, the minimum number of four patients were recruited into Cohort A.
  • Patients #2, 3 and 4 each received weekly infusions of 90µM of MTX110, the expected optimum dose, and remain in the study.
  • GBM universally recurs and once it does median overall survival according to a retrospective analysis of 299 patients reported in the Journal of Neuro-Oncology is 6.5 months1.

First Citizens Bank Joins with Teen Cancer America for 2024 'Month of Love' Campaign

Retrieved on: 
Thursday, February 1, 2024
TCA, Hospital, National Cancer Institute, Research, Candy, Duke Cancer Institute, Vanderbilt University, First Citizens BancShares, Adolescence, Social media, Quality of life, Cancer, Nursing

RALEIGH, N.C., Feb. 1, 2024 /PRNewswire/ -- February is nonprofit Teen Cancer America's (TCA) "Month of Love," and First Citizens Bank is encouraging everyone to share the love and give hope to young people with cancer.

Key Points: 
  • RALEIGH, N.C., Feb. 1, 2024 /PRNewswire/ -- February is nonprofit Teen Cancer America's (TCA) "Month of Love," and First Citizens Bank is encouraging everyone to share the love and give hope to young people with cancer.
  • "TCA is the only national nonprofit dedicated to this age group, which has unique physical and psychological needs.
  • We're proud to support TCA's efforts to improve medical outcomes, enhance treatment experiences and provide facilities and programs designed especially for these young people.
  • Thanks to the bank's support, North Carolina is the first and only state in the nation to have adolescent and young adult programs in every one of the state's National Cancer Institute-designated cancer centers.

Tigerlily Foundation and Labcorp Launch I AM INCLUDED Framework to Increase Clinical Trial Diversity, Accelerate Delivery of Innovative Cancer Treatments

Retrieved on: 
Thursday, November 16, 2023
UCSF School of Medicine, Health equity, Meharry Medical College, Labcorp, Food, National Cancer Institute, Tigerlily, Morehouse School of Medicine, Disease, Duke Cancer Institute, Clinical trial, Mortality, Breast cancer, NCI, Patient, FDA, Person, Partnership, Pharmaceutical industry, Nursing, University, BURLINGTON

BURLINGTON, N.C. and WASHINGTON, Nov. 16, 2023 /PRNewswire/ -- Today, the Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, and Labcorp , a global leader of innovative and comprehensive laboratory services, announced the launch of I AM INCLUDED , a co-developed, modernized, multi-stakeholder framework for sharing best practices of U.S. diverse clinical trial site leaders for inclusive cancer clinical trials.

Key Points: 
  • BURLINGTON, N.C. and WASHINGTON, Nov. 16, 2023 /PRNewswire/ -- Today, the Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, and Labcorp , a global leader of innovative and comprehensive laboratory services, announced the launch of I AM INCLUDED , a co-developed, modernized, multi-stakeholder framework for sharing best practices of U.S. diverse clinical trial site leaders for inclusive cancer clinical trials.
  • Labcorp and Tigerlily then jointly hosted Patient Listening and Clinical Site Listening Summits to discuss health equity and diversity in cancer clinical trials.
  • Following the listening summits, I AM INCLUDED was developed as a transformational, actionable framework to provide proven and successful actions and serve as a guide for clinical trial site leaders to diversify enrollment in clinical research.
  • "Partnership without action is just admiring the problem," said Maimah Karmo, founder and CEO, Tigerlily Foundation.

First Citizens Bank Launches 2023 Teen Cancer America Campaign

Retrieved on: 
Wednesday, November 1, 2023
Adolescence, First Citizens Bank of South Carolina, Social media, UNC Lineberger Comprehensive Cancer Center, Ward, TCA, First Citizens BancShares, AYA, Research, Citizenship, National Cancer Institute, Quality of life, University of North Carolina at Charlotte, Duke Cancer Institute, Credit card, Internet, Hospital, Young adult, Atrium Health Wake Forest Baptist, University, Vanderbilt, Cancer, Patient, Birth control, Nursing, Pharmaceutical industry

RALEIGH, N.C., Nov. 1, 2023 /PRNewswire/ -- What if you could help a young person with cancer?

Key Points: 
  • That's the message behind First Citizens Bank's 2023 campaign to raise awareness and money for nonprofit Teen Cancer America (TCA), which develops specialized programs and facilities for teens and young adults with cancer.
  • First Citizens is encouraging everyone to donate to the nonprofit this fall and throughout the holiday season.
  • "By supporting Teen Cancer America, we can make a tremendous difference in the lives of the 90,000 young people diagnosed with cancer each year," said Jeff Ward, First Citizens' chief strategy officer and TCA national board member.
  • First Citizens and TCA recently helped dedicate a new infusion clinic at the N.C. Basnight Cancer Hospital at the University of North Carolina's Lineberger Comprehensive Cancer Center in Chapel Hill, N.C.

Mays Cancer Center: Targeting certain molecular interactions could yield new strategies for treating prostate cancer

Retrieved on: 
Friday, October 20, 2023
United States Secretary of Education, Research, Longevity, Duke Cancer Institute, Ageing, Molecular biology, Duke University, Nursing, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Dentistry, Doctor of Philosophy, Health, Prostate cancer, Protein, Cell, California Institute for Regenerative Medicine, Chromatin, National Cancer Institute, Male, Biotechnology, Sam, Disease, Medicine, University of Texas Health Science Center at San Antonio, Teaching, School, University, UT Health San Antonio Cancer Center, Public, Office of Inspector General, U.S. Department of Health and Human Services, University of Texas System, Molecular medicine, AR, Patient, Chromosome, SAN, DNA, Pharmaceutical industry, Vaccine, Advertising, Molecular Cell, Cancer

SAN ANTONIO, Oct. 20, 2023 /PRNewswire-PRWeb/ -- Research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered that altering certain molecular interactions could yield new strategies for treating prostate cancer and related diseases.

Key Points: 
  • SAN ANTONIO, Oct. 20, 2023 /PRNewswire-PRWeb/ -- Research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered that altering certain molecular interactions could yield new strategies for treating prostate cancer and related diseases.
  • "Our results provide molecular insights for potential therapeutic strategies to treat prostate cancer and other AR-involved diseases by targeting AR multivalent interactions," said Zhijie "Jason" Liu, PhD, associate professor and CPRIT Scholar in Cancer Research with Mays Cancer Center and the Institute of Biotechnology of the Department of Molecular Medicine at UT Health San Antonio.
  • The Mays Cancer Center at UT Health San Antonio is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.

WebMD Announces 16th Annual 2023 Health Heroes

Retrieved on: 
Wednesday, October 11, 2023
Diagnosis, Neuroscience, COVID-19, Osteochondrodysplasia, Skull, Bias, Family, The Children's Hospital, Machine learning, MS, Headache, COVID, Driving Force, Sickle cell disease, Rickets, Hospital, Bone tumor, Heart Trouble (album), CDC, Genetics, Disease, WHO, Patient, World Health Organization, Chordoma, Movement, Education, Long, CRISPR, HCA Healthcare, Clinical trial, Duke Cancer Institute, Public policy, Duke University, Genetic disorder, King Fahad Specialist Hospital Dammam, Bangladesh Technical Education Board, Jansen, Tissue, Volunteering, Korea Disease Control and Prevention Agency, Grey, Child, National Institutes of Health, Sarah Cannon Research Institute, Life, WebMD, Research, NIH, Cognitive science, Nursing, Pharmaceutical industry, Vaccine, MD, Long COVID

NEWARK, N.J., Oct. 11, 2023 /PRNewswire/ -- WebMD announced today the winners of the 2023 WebMD 16th annual Health Heroes Awards, which includes 4 categories: Lifelong Advocate, Patient Pioneer, Selfless Survivor and Driving Force.

Key Points: 
  • NEWARK, N.J., Oct. 11, 2023 /PRNewswire/ -- WebMD announced today the winners of the 2023 WebMD 16th annual Health Heroes Awards, which includes 4 categories: Lifelong Advocate, Patient Pioneer, Selfless Survivor and Driving Force.
  • "This year's Health Heroes are not only doing amazing things but they also have data or other measurable results that demonstrate the impact of their work," said Dr. John Whyte, Chief Medical Officer of WebMD.
  • With their findings in hand, they began meeting with public health leadership at the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and World Health Organization (WHO) to forge a path toward more research on Long COVID.
  • For additional information on the 2023 WebMD Health Heroes, click here: https://www.webmd.com/healthheroes/default.htm

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC

Retrieved on: 
Sunday, September 10, 2023
WCLC, AMGN, KRAS, Duke University, Amgen, Duke Cancer Institute, DCR, Platinum, Trae tha Truth, Lung cancer, International Association, Medicine, NSCLC, Carboplatin, PFS, Drug resistance, Progression-free survival, Patient, Anemia, Heath Robinson (codebreaking machine), Pemetrexed, Safety, PD-L1, Conference, ORR, Pharmaceutical industry, Fine chemical, Research

THOUSAND OAKS, Calif., Sept. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS® (sotorasib) with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). These results were featured in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) in Singapore on Sunday, September 10.

Key Points: 
  • In assessable patients in the second-line setting (n=13), the ORR was 54%, with a DCR of 85% (95% CI: 54.6, 98.1).
  • "Notably, these results follow and further expand upon the Phase 2 investigator-led data demonstrating favorable efficacy and safety of LUMAKRAS plus carboplatin and pemetrexed in the first-line treatment of patients with KRAS G12C-mutated NSCLC."
  • The LUMAKRAS plus chemotherapy combination reported treatment-related adverse events (TRAEs) consistent with LUMAKRAS and other platinum doublet-based approaches.
  • "The CodeBreaK 101 results show exciting efficacy with sotorasib plus chemotherapy and, importantly for a combination treatment, a safety profile consistent with the individual therapies.

The Gray Foundation Announces $25 Million in New Funding for BRCA-Related Cancer Research

Retrieved on: 
Thursday, August 10, 2023
Biotechnology, Health, Science, Research, Oncology, Yale School of Medicine, Science of team science, Cleveland Clinic, University, Duke Cancer Institute, Grey, Doctor of Philosophy, Penn, Memorial Sloan Kettering Cancer Center, Cancer, Weill Cornell Medicine, BRCA, Johns Hopkins School of Medicine, Cleveland, University of Texas System, Pharmaceutical industry, Management, MD

The Gray Foundation today announced $25 million in funding for 7 research teams to study new approaches for prevention, early detection, and interception of BRCA-related cancers.

Key Points: 
  • The Gray Foundation today announced $25 million in funding for 7 research teams to study new approaches for prevention, early detection, and interception of BRCA-related cancers.
  • The new grants are part of the Foundation’s ongoing Team Science program, which funds innovative BRCA-related collaborative research.
  • The selected multi-institutional, multi-disciplinary teams will commence studies into a variety of topics related to prevention, early detection, and interception.
  • We are inspired to support this cutting-edge research across institutions as we continue to make progress in early detection, prevention, and interception of BRCA-related cancers.”
    With these grants, the Gray Foundation has committed $187 million to supporting BRCA research.